"BCG Vaccine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An active immunizing agent and a viable avirulent attenuated strain of Mycobacterium tuberculosis, var. bovis, which confers immunity to mycobacterial infections. It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity.
| Descriptor ID |
D001500
|
| MeSH Number(s) |
D20.215.894.135.825.100
|
| Concept/Terms |
BCG Vaccine- BCG Vaccine
- Vaccine, BCG
- Bacillus Calmette Guerin Vaccine
- Calmette Guerin Bacillus Vaccine
- Calmette's Vaccine
- Calmette Vaccine
- Calmettes Vaccine
- Vaccine, Calmette's
|
Below are MeSH descriptors whose meaning is more general than "BCG Vaccine".
Below are MeSH descriptors whose meaning is more specific than "BCG Vaccine".
This graph shows the total number of publications written about "BCG Vaccine" by people in this website by year, and whether "BCG Vaccine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 0 | 1 | 1 |
| 2019 | 2 | 1 | 3 |
| 2020 | 1 | 1 | 2 |
| 2022 | 1 | 2 | 3 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "BCG Vaccine" by people in Profiles.
-
Contieri R, Grajales V, Tan WS, Martini A, Sood A, Hensley P, Bree K, Lobo N, Nogueras-Gonzalez GM, Guo CC, Navai N, Dinney CP, Kamat AM. Impact of age >70?years on oncological outcomes in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Gu?rin. BJU Int. 2024 01; 133(1):63-70.
-
Morales CG, Jimenez NR, Herbst-Kralovetz MM, Lee NR. Novel Vaccine Strategies and Factors to Consider in Addressing Health Disparities of HPV Infection and Cervical Cancer Development among Native American Women. Med Sci (Basel). 2022 09 13; 10(3).
-
Singh S, Saavedra-Avila NA, Tiwari S, Porcelli SA. A century of BCG vaccination: Immune mechanisms, animal models, non-traditional routes and implications for COVID-19. Front Immunol. 2022; 13:959656.
-
Murakami K, Kamat AM, Dai Y, Pagano I, Chen R, Sun Y, Gupta A, Goodison S, Rosser CJ, Furuya H. Application of a multiplex urinalysis test for the prediction of intravesical BCG treatment response: A pilot study. Cancer Biomark. 2022; 33(1):151-157.
-
Toraih EA, Sedhom JA, Dokunmu TM, Hussein MH, Ruiz EML, Muthusamy K, Zerfaoui M, Kandil E. Hidden in plain sight: The effects of BCG vaccination in the COVID-19 pandemic. J Med Virol. 2021 04; 93(4):1950-1966.
-
Tiwari S, Dutt TS, Chen B, Chen M, Kim J, Dai AZ, Lukose R, Shanley C, Fox A, Karger BR, Porcelli SA, Chan J, Podell BK, Obregon-Henao A, Orme IM, Jacobs WR, Henao-Tamayo M. BCG-Prime and boost with Esx-5 secretion system deletion mutant leads to better protection against clinical strains of Mycobacterium tuberculosis. Vaccine. 2020 10 21; 38(45):7156-7165.
-
Jamil ML, Deebajah M, Sood A, Alanee S. Combination of pembrolizumab and BCG treatment after endoscopic ablation of high-risk superficial upper urinary tract urothelial carcinoma in patients not candidates for radical nephroureterectomy: protocol for phase-II study. BMJ Open. 2019 12 03; 9(12):e027066.
-
Jamil ML, Deebajah M, Sood A, Robinson K, Rao K, Sana S, Alanee S. Protocol for phase I study of pembrolizumab in combination with Bacillus Calmette-Gu?rin for patients with high-risk non-muscle invasive bladder cancer. BMJ Open. 2019 07 17; 9(7):e028287.
-
Tiwari S, Casey R, Goulding CW, Hingley-Wilson S, Jacobs WR. Infect and Inject: How Mycobacterium tuberculosis Exploits Its Major Virulence-Associated Type VII Secretion System, ESX-1. Microbiol Spectr. 2019 05; 7(3).
-
Morales A, Cohen Z. Mycobacterium phlei cell wall-nucleic acid complex in the treatment of nonmuscle invasive bladder cancer unresponsive to bacillus Calmette-Guerin. Expert Opin Biol Ther. 2016; 16(2):273-83.